Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CHEK-STP114 | Human | NY-ESO-1 specific TCR-HEK293 cell line |
FACS analysis NY-ESO-1 specific TCR on NY-ESO-1 specific TCR-HEK293 cell line.
FACS assay shows that PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein can bind to NY-ESO-1 specific TCR-HEK293 cell line. NY-ESO-1 specific TCR-HEK293 cell line was red line, Negative control HEK293 cells was grey line (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Cancer vaccine NY-ESO-1 (Ludwig Institute/Peking University/Jewim Pharmaceutical) | Phase 2 Clinical | Ludwig Institute For Cancer Research | Liver Neoplasms; Melanoma | Details | |
| Anti-NY-ESO-1 TCR-T cell theray (Shenzhen BinDeBio) | Phase 2 Clinical | Shenzhen Bindebio Ltd | Stomach Neoplasms; Esophageal Neoplasms; Glioma; Carcinoma, Hepatocellular | Details | |
| Anti-NY-ESO-1 murine TCR transduced autologous peripheral blood lymphocytes (Albert Einstein College of Medicine/NCI) | Phase 1 Clinical | Albert Einstein College Of Medicine Inc, National Cancer Institute | Neoplasms | Details | |
| Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes (Roswell) | CD8-TCR-T cells; NY-ESO-1/CD8/HL AA2.1-19305dp-TCR-T cells | Phase 2 Clinical | Roswell Park Cancer Institute | Neoplasms | Details |
| LYL-132 | LYL-132; GSK-4427296 | Phase 1 Clinical | Lyell Immunopharma Inc | Solid tumours; Neoplasms | Details |
| GSK-3845097 | GSK-3845097; GSK3845097 | Glaxosmithkline Plc | Details | ||
| GSK-3901961 | GSK-3901961; GSK3901961 | Glaxosmithkline Plc | Details | ||
| HBI-0201-ESO TCRT | HBI-0201-ESO TCRT | Phase 2 Clinical | Hadassah Medical Organization | Ovarian Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Sarcoma, Synovial; Sarcoma; Neuroblastoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis | Details |
| mipetresgene autoleucel | TBI-1301 | Phase 2 Clinical | Takara Bio Inc | Liver Neoplasms; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Lung Neoplasms; Melanoma | Details |
| NY-ESO-1 TCR Engineered T Cells and HSCs (Roswell Park Cancer Institute) | Phase 1 Clinical | Roswell Park Cancer Institute | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details | |
| NY-ESO-1 TCR | Phase 2 Clinical | Kite Pharma, National Cancer Institute | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Sarcoma, Synovial; Sarcoma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Meningioma | Details | |
| Letetresgene autoleucel | GSK-3377794; GSK-794 | Phase 2 Clinical | Adaptimmune Llc | Ovarian Neoplasms; Neoplasms; Multiple Myeloma; Melanoma | Details |
| TCR Affinity Enhancing Specific T cell Therapy | TAEST-16001 | Phase 2 Clinical | Guangzhou Xiangxue Pharmaceutical Co Ltd, Guangzhou Institute Of Respiratory Health | Liver Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Urinary Bladder Neoplasms; Osteosarcoma; Sarcoma; Breast Neoplasms; Bone Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Rasdegafusp alfa | CDX-1401 | Phase 2 Clinical | Ludwig Institute For Cancer Research | Prostatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Endometrial Neoplasms; Uterine Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Astrocytoma; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Skin Melanoma; Brain Neoplasms; Oligodendroglioma; Urinary Bladder Neoplasms; Neoplasms; Glioblastoma; Colonic Neoplasms; Leukemia, Myelomonocytic, Chronic; Anemia, Refractory; Myelodysplastic Syndromes; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Ovarian Neoplasms | Details |
| MT-601 | MT601 | Phase 1 Clinical | Marker Therapeutics Inc | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details |
| Autologous NY-ESO-1-targeting dendritic cell vaccine (Roswell Park Cancer Institute) | DEC-205-NY-ESO-1; vCP2292; VCP-2292 | Phase 2 Clinical | Roswell Park Cancer Institute | Ovarian Neoplasms; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma | Details |
This web search service is supported by Google Inc.
A-Z
